Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 14/20 | 0.53 |
| ▸ | PPARA | Q07869 | 18/20 | 0.52 |
| ▸ | PPARD | Q03181 | 12/20 | 0.47 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6575581 | 0.90 | PPARG (0.45) | PPARGPPARAPPARDCXCR2 | |
| SCHEMBL5375683 | 0.90 | PPARG (0.45) | PPARGPPARAPPARDCXCR2 | |
| SCHEMBL5409308 | 0.90 | PPARA (0.63) | PPARGPPARAPPARD | |
| SCHEMBL4795714 | 0.82 | PPARG (0.61) | PPARGPPARAPPARD | |
| SCHEMBL4798958 | 0.79 | PPARG (0.61) | PPARGPPARAPPARD | |
| SCHEMBL2855147 | 0.79 | TACR1 (0.48) | PPARGPPARACXCR2 | |
| SCHEMBL2855146 | 0.79 | TACR1 (0.48) | PPARGPPARACXCR2 | |
| SCHEMBL4798962 | 0.79 | PPARG (0.61) | PPARGPPARAPPARD | |
| SCHEMBL4451910 | 0.79 | PPARA (0.51) | PPARGPPARAPPARD | |
| SCHEMBL5365685 | 0.78 | PPARA (0.55) | PPARGPPARAPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7309720-B2 | 2-ethoxy-3-phenylpropionic acid derivatives for the treatment of lipid disorders | ASTRAZENECA AB (SE) | 2007-12-18 | — | — | US | disclosed |
| US-20060178432-A1 | 2-Ethoxy-3-phenylpropionic acid derivatives for the treatment of lipid disorders | ASTRAZENECA AB (SE) | 2006-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178432-A1 | 2-Ethoxy-3-phenylpropionic acid derivatives for the treatment of lipid disorders | LIPC, PNLIP, CPT1A | PPARG 72/4885PPARA 34/4885PPARD 210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.